REUTERS
November 30, 2022 at 11:55 JST
The head office of Japanese pharmaceutical company Eisai Co., Ltd. is seen in Tokyo July 20, 2009. (REUTERS)
SAN FRANCISCO--An experimental Alzheimer’s disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. [Read More]
A peek through the music industry’s curtain at the producers who harnessed social media to help their idols go global.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series about Japanese-Americans and their memories of World War II
